Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label study evaluating the antiviral activity and safety of Fuzeon [enfuvirtide] in triple-class experienced HIV-1 infected patients changing their therapy to a standard of care regimen which includes initiating an integrase inhibitor in an expanded access program plus optimized background.

Next Previous
Trial Profile

An open label study evaluating the antiviral activity and safety of Fuzeon [enfuvirtide] in triple-class experienced HIV-1 infected patients changing their therapy to a standard of care regimen which includes initiating an integrase inhibitor in an expanded access program plus optimized background.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enfuvirtide (Primary) ; Antiretrovirals; Raltegravir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms AMICI
  • Sponsors Roche

Most Recent Events

  • 28 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
  • 17 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
  • 11 Jun 2008 Status changed from recruiting to in progress as reported by Roche.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top